Investigating the role of the microbiome and inflammation in acute and chronic pain in patients with sickle cell disease
研究微生物组和炎症在镰状细胞病患者急性和慢性疼痛中的作用
基本信息
- 批准号:10462603
- 负责人:
- 金额:$ 68.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:Absence of pain sensationAccident and Emergency departmentAcuteAcute PainAdolescentAdultAffectAgeBacterial TranslocationBiological AssayBiological FactorsBiologyBloodCellsChronicChronic Fatigue SyndromeClinical ResearchComplex Regional Pain SyndromesComplicationDataDevelopmentDiseaseEmergency department visitFecesFrequenciesGenderGenesGenetic TranscriptionGoalsHealthHealth Care CostsHemolysisHospitalizationImmune systemImmunologic ReceptorsImpairmentIncidenceInflammationInflammatoryInflammatory ResponseInheritedInpatientsIrritable Bowel SyndromeKnowledgeLeadLigationLipopolysaccharidesMeasuresMigraineModelingNervous system structureNociceptorsOpioidOutcomePainPain managementPatient Outcomes AssessmentsPatientsPattern recognition receptorPeripheralPersonsPlasmaPlayPopulationQuality of lifeRaceRecurrenceReperfusion InjuryReporterResearchRheumatoid ArthritisRibosomal DNARoleSeveritiesSiblingsSickle CellSickle Cell AnemiaTLR4 geneTestingVertebral columnWorkbasecare seekingchemokinechemotherapychronic inflammatory diseasechronic painchronic pelvic painclinical phenotypecytokinedaily paindebilitating paindysbiosiseffective therapygut microbiotaimmunoregulationimprovedinflammatory milieuintestinal barriermicrobialmicrobiomemicrobiotamicroorganism antigenmultidisciplinarynovelopioid sparingperipheral painresponsesicklingside effectsocial stigmatargeted treatment
项目摘要
PROJECT SUMMARY/ABSTRACT
The overall goals of the proposed work are to investigate the role of the microbiome and inflammation in acute
and chronic pain in patients with sickle cell disease (SCD). Intermittent, excruciating acute pain accounts for
the majority of emergency department visits and hospitalizations for patients with SCD and the frequency of
these episodes increase with age. Chronic, debilitating, daily pain also occurs in ~40% of adolescents and
adults with SCD and the incidence and severity of chronic pain also increases with age. A critical knowledge
gap exists in the identification of reasons other than chronic sickling that contribute to the unpredictable clinical
phenotype of frequent acute and chronic daily pain. Opioids are the backbone treatment for both acute and
chronic SCD pain; however they often provide ineffective analgesia and can lead to significant side effects and
stigma. An increased understanding of the biology of acute and chronic SCD pain is needed in order to
develop opioid-sparing, targeted therapies to improve the quality of life of patients with SCD. Alterations in the
intestinal microbiota or dysbiosis, a known driver of chronic inflammation, have not been explored in SCD but
play a role in other chronic inflammatory diseases and pain-related disorders. Dysbiosis has been associated
with pain in rheumatoid arthritis, migraines, chronic pelvic pain and chemotherapy-induced pain. Dysbiosis can
lead to a “leaky” intestinal barrier resulting in bacterial translocation into the blood. Bacterial translocation (i.e.,
systemic microbial antigen exposure) can trigger chronic inflammation which can sensitize peripheral pain
nociceptors and result in recurrent acute and chronic pain. Immune regulation of this inflammatory response
can modulate the inflammatory impact on pain. Nervous system sensitization occurs in SCD patients.
However, the biologic factors that lead to nervous system sensitization in SCD are unknown. Thus,
investigating the connection between the microbiome, inflammation and SCD pain is important. In this
proposal, we will investigate whether microbial antigens from intestinal microbiota alterations drive
inflammation and pain in patients with SCD. The following aims are proposed: 1) Examine the relationship
between systemic microbial antigen levels, intestinal microbiota composition and diversity and the systemic
inflammatory state in patients with SCD and healthy race-matched controls and 2) Investigate whether acute
and chronic pain in SCD patients is associated with increases in systemic microbial antigen exposure and an
elevated inflammatory state. Our collaborative and multidisciplinary team has clinical and research expertise in
SCD pain biology, inflammation, microbiome and SCD patient-reported outcomes. We will utilize a multifaceted
approach to investigate how microbial exposure and host inflammatory response impacts the expression of
SCD pain. Our work has the potential to identify targets for novel opioid-sparing pain treatments that will
decrease patient suffering.
项目摘要/摘要
拟议工作的总体目标是研究微生物组和注射急性的作用
镰状细胞病(SCD)患者的慢性疼痛。间歇性,令人痛苦的急性疼痛
SCD患者的大多数急诊科和住院
这些发作随着年龄的增长而增加。慢性,使人衰弱的每日疼痛也发生在约40%的青少年和
患有SCD的成年人以及慢性疼痛的事件和严重程度也随着年龄的增长而增加。批判知识
差距存在于鉴定出慢性病以外的其他原因,这导致了不可预测的临床
经常急性和慢性疼痛的表型。阿片类药物是急性和
慢性SCD疼痛;但是,它们通常提供无效的镇痛,并可能导致重大副作用,并且
柱头。为了使急性和慢性SCD疼痛的生物学有更多的了解
开发具有阿片类药物的目标疗法,以改善SCD患者的生活质量。改变
肠道菌群或营养不良是慢性感染的已知驱动力,尚未在SCD中探索
在其他慢性炎症性疾病和与疼痛有关的疾病中发挥作用。营养不良一直关联
类风湿关节炎,偏头痛,慢性骨盆疼痛和化学疗法引起的疼痛的疼痛。营养不良可以
导致“泄漏”的肠道屏障,导致细菌转移到血液中。细菌易位(即
全身微生物抗原暴露)会触发慢性炎症,这可能会感觉到周围疼痛
伤害感受器,导致复发性急性和慢性疼痛。免疫调节这种炎症反应
可以调节对疼痛的炎症影响。 SCD患者发生神经系统敏感性。
但是,导致SCD神经系统敏感性的生物学因素尚不清楚。那,
研究微生物组,注射和SCD疼痛之间的联系很重要。在这个
提案,我们将调查肠道微生物改变的微生物抗原是否驱动
SCD患者的炎症和疼痛。提出了以下目的:1)检查关系
在全身微生物抗原水平,肠道微生物群组成和多样性之间
SCD和健康匹配对照患者的炎症状态,2)研究是否急性
SCD患者的慢性疼痛与全身微生物抗原暴露的增加有关
炎症状态升高。我们的合作和多学科团队具有临床和研究专业知识
SCD疼痛生物学,感染,微生物组和SCD患者报告的结果。我们将利用一个多方面的
研究微生物暴露和宿主炎症反应如何影响表达的方法
SCD疼痛。我们的工作有可能确定新型阿片类药物疼痛治疗的目标
减少患者的痛苦。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Preliminary construct validity of patient-reported outcomes to assess chronic pain in adults with sickle cell disease.
- DOI:10.1182/bloodadvances.2023009707
- 发表时间:2023-07-25
- 期刊:
- 影响因子:7.5
- 作者:Mucalo, Lana;Field, Joshua J.;Highland, Janelle;Khan, Hamda;Hankins, Jane S.;Singh, Ashima;Brandow, Amanda M.
- 通讯作者:Brandow, Amanda M.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Amanda M Brandow其他文献
Amanda M Brandow的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Amanda M Brandow', 18)}}的其他基金
Sickle Cell Improvement: ENhancing Care in the Emergency Department (SCIENCE)
镰状细胞病的改善:加强急诊科的护理(科学)
- 批准号:
10311624 - 财政年份:2021
- 资助金额:
$ 68.33万 - 项目类别:
The Inflammatory Index as a Biomarker for Pain in Patients with Sickle Cell Disease
炎症指数作为镰状细胞病患者疼痛的生物标志物
- 批准号:
10618737 - 财政年份:2019
- 资助金额:
$ 68.33万 - 项目类别:
Investigating the role of the microbiome and inflammation in acute and chronic pain in patients with sickle cell disease
研究微生物组和炎症在镰状细胞病患者急性和慢性疼痛中的作用
- 批准号:
9769125 - 财政年份:2018
- 资助金额:
$ 68.33万 - 项目类别:
Investigating the role of the microbiome and inflammation in acute and chronic pain in patients with sickle cell disease
研究微生物组和炎症在镰状细胞病患者急性和慢性疼痛中的作用
- 批准号:
10000989 - 财政年份:2018
- 资助金额:
$ 68.33万 - 项目类别:
Peripheral Sensitization as a Novel Mechanism for Pain in Sickle Cell Disease
外周敏化作为镰状细胞病疼痛的新机制
- 批准号:
8849493 - 财政年份:2013
- 资助金额:
$ 68.33万 - 项目类别:
Peripheral Sensitization as a Novel Mechanism for Pain in Sickle Cell Disease
外周敏化作为镰状细胞病疼痛的新机制
- 批准号:
8580484 - 财政年份:2013
- 资助金额:
$ 68.33万 - 项目类别:
Peripheral Sensitization as a Novel Mechanism for Pain in Sickle Cell Disease
外周敏化作为镰状细胞病疼痛的新机制
- 批准号:
8720808 - 财政年份:2013
- 资助金额:
$ 68.33万 - 项目类别:
Peripheral Sensitization as a Novel Mechanism for Pain in Sickle Cell Disease
外周敏化作为镰状细胞病疼痛的新机制
- 批准号:
9304263 - 财政年份:2013
- 资助金额:
$ 68.33万 - 项目类别:
相似海外基金
Development of a regional anesthesia guidance system to increase patient access to opioid-sparing analgesia for hip fracture pain
开发区域麻醉引导系统,以增加患者获得髋部骨折疼痛的阿片类药物保留镇痛的机会
- 批准号:
10759550 - 财政年份:2023
- 资助金额:
$ 68.33万 - 项目类别:
PAINED: Project Addressing INequities in the Emergency Department
痛苦:解决急诊科不公平问题的项目
- 批准号:
10537743 - 财政年份:2022
- 资助金额:
$ 68.33万 - 项目类别:
Oral N2O Therapy in Treating Acute Vaso-Occlusive Pain in Sickle Cell Disease
口服 N2O 疗法治疗镰状细胞病急性血管闭塞性疼痛
- 批准号:
10507724 - 财政年份:2022
- 资助金额:
$ 68.33万 - 项目类别:
2/2: Sickle Cell Disease Treatment with Arginine Therapy (STArT) trial
2/2:精氨酸疗法治疗镰状细胞病 (START) 试验
- 批准号:
10681380 - 财政年份:2020
- 资助金额:
$ 68.33万 - 项目类别:
IM Ketamine for rapid reduction of suicidal thoughts in high-risk emergency room patients: a midazolam-controlled trial
肌内注射氯胺酮可快速减少高危急诊室患者的自杀念头:一项咪达唑仑对照试验
- 批准号:
10469693 - 财政年份:2020
- 资助金额:
$ 68.33万 - 项目类别: